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Introduction
Type 1 diabetes (T1D) is strongly associated with autoantibodies (A) against zinc transporter 8 (ZnT8A), glutamic acid decarboxylase 65 (GADA), insulinoma-associated antigen-2 (IA-2A) and insulin (IAA) (reviewed in [1] ). Together or alone, they are important not only for classification of diabetes at the time of clinical onset, but also for the prediction of T1D in subjects at risk [2] [3] [4] . More than 90% of patients with T1D have multiple autoantibodies, and less than 5% of T1D patients were found negative for any of these four islet autoantibodies at clinical onset [5] . However, it has been suggested that islet autoantibody negative individuals may be positive for yet other beta-cell autoantigen-specific autoantibodies [5] . Neuropeptide Y (NPY) was previously reported as a minor autoantigen in newly diagnosed T1D patients [6] .
NPY is a neurotransmitter widely expressed within the central and peripheral nervous systems affecting vasoconstriction, insulin secretion and food intake [7] [8] . NPY has also been demonstrated in islet cells and pancreatic nerve fibers [9] . Furthermore, a single nucleotide polymorphism (SNP) at rs16139 (T1128C) identified an amino acid substitution from Leucine (L) to Proline (P) (L7P) in the signal peptide [10] . The minor allele (P) correlated with elevated NPY levels in plasma [11] perhaps due to an increased biosynthesis [12] [13] . It was suggested that the L7P affects NPY secretion as a consequence of a modified secondary and tertiary structure [12] . It is therefore of interest that the minor allele was associated with atherosclerosis [14] , impaired glucose tolerance [15] as well as with a three-to four-fold increased risk for Type 2 diabetes (T2D) [15] [16]. More importantly, the minor allele also increased the risk for retinopathy [14] and nephropathy [17] in patients with T2D.
Autonomic neuropathy in patients with T1D was associated with impaired NPY responses to insulin-induced hypoglycaemia [18] . As T1D neuropathy was also associated with GADA [19] [20], we tested the hypothesis that NPY autoantibodies (NPYA) may be present in T1D patients with neuropathy and that NPYA would be related to the rs16139 polymorphism.
The aims of this study were to 1) develop a radiobinding assay (RBA) for NPY-L (Leucine) and NPY-P (Proline) autoantibodies (NPYA) in controls and in patients with long-term T1D and T2D, 2) relate both NPY-LA and NPY-PA with autoantibodies against ZnT8R (Arginine), ZnT8W (Tryptophan), ZnT8Q (Glutamine), GAD65 and IA-2; and 3) study these autoantibody levels during follow-up of T1D patients tested for neuropathy.
Materials and Methods

Patient and control samples
A total of 100 patients, 1.5-18.8 years of age, with T1D diagnosed in 1996-2001 were studied (Table 1) . Serum samples from 48 long-term T1D and 26 long-term T2D patients were collected in 1998 at the Clinic of Diabetes at Skåne University Hospital in Malmö, Sweden (Table 2) . A subgroup of 32 patients with long-term T1D, first seen in 1998, was followed-up in 2005 (Table   2 ). Sera for control samples were obtained from 398 healthy blood donors at 19-81 years of age (Table 2 ).
Nerve function tests during follow-up
The long-term T1D patients underwent peripheral and cardiac autonomic nerve function tests during the follow-up in 2005 (n=31; Table 2 ). The peripheral nerve function (peripheral neuropathy) was evaluated by measurement of conduction velocity (CV) and amplitude (AMP) of the sural and peroneal nerves in the lower extremities and calculated as a mean expressed in age-corrected values [Z-score in standard deviations (SD)]. A composite Z-score leg, reflecting the nerve function in the leg, was calculated: (Z-score CV peroneal nerve + Z-score CV sural nerve + Z-score AMP sural nerve)/3. The summation of nerve conduction attributes has been used elsewhere [21] . The cardiac autonomic nerve test (autonomic neuropathy) of the parasympathetic vagal nerve function (E/I ratio) was also tested [22] . The E/I ratio was calculated as the mean of the longest R-R interval during expiration (E) divided by the mean of the shortest R-R interval during inspiration (I) and expressed in age-corrected values [Z-scores in SD]. E/I Z-score values less than −1.64 SD (95% confidence interval, one-sided test) below the age-related reference values were considered as abnormal [22].
Subcloning of pJ201prepro-NPY
Prepro-Neuropeptide Y (NPY) (aa 1-97) cDNA was inserted in a de novo synthesised pJ201 vector (2759 bp) (DNA 2.0, Menlo Park, CA, USA) with both restriction cloning sites of Xho1 and Not1 at the 5´ end and 3´end of the insert. The pJ201NPY cDNA (2 µg) was cut with two restriction enzymes, Xho1 and Not1 (FastDigest™, Fermentas, Helsingborg, Sweden). The NPY insert was subcloned into the pTnT™ vector (2871 bp) (Promega, Madison, WI, USA) and transformed using DH5α E.coli competent cells (Invitrogen AB, Stockholm, Sweden). The pThNPY plasmid DNA was extracted using the QiaPrep Spin Miniprep Kit (QIAGEN AB, Solna, Sweden) according to manufacturer's instructions followed by sequencing using (3700/3730 BigDye Terminator 3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) at the Region Skånes Competence Centre (RSKC) in Malmö, Sweden.
Generation of pTnTprepro-NPY SNP T1128C-Proline variant
Both forward and reverse primers were designed according to manufacturer's instructions (DNA Technology, Risskov, Denmark). A Phusion™ site directed mutagenesis Kit (Thermo Fisher Scientific, Leicestershire, UK) was used to obtain Proline (P) in substitution for Leucine (L) (L7P) of the prepro-NPY insert. The pThNPY-P variant was transformed in DH5α E.coli competent cells prior plasmid DNA extraction and sequencing as previously described.
Radiolabeling of prepro-NPY protein products
Both pThNPY-L and pThNPY-P (1µg each) were subjected to in vitro coupled transcription Figure 1 ) generated by in vitro transcription translation as described [24] . Patient and control samples were analysed for autoantibodies in parallel on the same plate to reduce assay variances.
ZnT8, GAD65, IA-2 autoantibody analyses
The RBA for each of individual ZnT8 autoantibody (ZnT8RA, ZnT8WA, ZnT8QA) was carried out as described [25] . Autoantibodies against GAD65 and IA-2 were similarly analyzed as described previously [26] . 
Statistical analysis
NPY and islet autoantibodies in controls, type 1 and type 2 diabetes patients
In the newly diagnosed T1D patients (n=100) NPY-LA or NPY-PA showed a frequency of 29%
for both autoantigens (Table 1) . NPY-LA and NPY-PA double positives were found in 20% of the newly diagnosed patients.
The long-term T1D (n=48) patients were diagnosed at 15-26 years of age compared to the T2D (n=26) patients diagnosed at 31-50 years of age ( Table 2 ). Duration of the disease was comparable between the two groups of patients. However, while all patients with long-term T1D
had low level of C-peptide, the long-term T2D patients showed a marked variability (Table 2) . A total of 32 T1D patients were re-examined after 21-50 years of disease ( Table 2) (Table 3) . NPY-LA and NPY-PA double positive T2D were 3/26 (11.5%).
The median levels of the two NPYA were different from the controls in both the T1D (NPY-LA: Compared to the controls, the frequencies of the ZnT8A variants were 40% for ZnT8RA (p<0.001), 40% for ZnT8WA (p<0.001) and 35% for ZnT8QA (p<0.001) in the T1D and 15%
(p=0.004), 12% (p=0.031) and 12% (p=0.031), respectively, in T2D patients ( Table 3 ). The median levels of all ZnT8A variants (ZnT8RA, ZnT8WA, ZnT8QA) were higher in long-term patients with both T1D (ZnT8RA, p<0.001; ZnT8WA, p<0.001; ZnT8QA, p<0.001) and in T2D
(ZnT8RA, p<0.001; ZnT8WA, p<0.001; ZnT8QA, p<0.001) compared to the controls ( Figure 3, 
panel B).
GADA and IA-2A were detected in 52% (p<0.001) and in 31% (p<0.001), respectively, of the long-term T1D patients compared to the controls (Table 3) but were negative in all T2D patients.
However, the median levels including also the samples below the cut-off of both GADA and IA-2A were higher in both patient groups compared to the controls (T1D: GADA p<0.001, IA-2A p<0.001; T2D; GADA p<0.001, IA-2A p=0.02) ( Figure 3 , panel C).
Combinations between NPYA and islet autoantibodies at baseline
We tested whether NPY-LA, NPY-PA, or both, occurred more often in patients with any of the ZnT8A variants, GADA or IA-2A. At baseline, neither of the single NPYA variants nor both of them taken together, appeared more often with ZnT8RA, ZnT8WA, ZnT8QA, GADA or IA-2A
in patients with long-term T1D (Table 4 ). However, in 3/6 (50%) of T2D patients NPYA were double positive with both ZnT8RA (p=0.028) and ZnT8WA (p=0.008). NPY-PA showed a substantial agreement with ZnT8WA (kappa 0.61, p=0.001) and a moderate agreement with ZnT8RA (kappa 0.51, p=0.001) in the T2D patients (Table 4) . Among the NPY-LA positive T1D patients 6/11 (55%) were also positive for NPY-PA (p=0.002). The two NPYA variants showed a moderate agreement (kappa 0.50, p=0.001) in T1D and a substantial agreement (kappa 0.61, p=0.001) in T2D patients (Table 4) .
Number of islet autoantibodies at baseline
Among the autoantibody positive (41/48, 85%) patients with long-term T1D, there were 25/48 (52%) positive for at least one ZnT8A variant, and 12/48 (25%) positive for all three ZnT8A (Table 3 ). Most of the T1D patients, 13/48 (27%) had one autoantibody, although 9/48 (19%)
were positive for four autoantibodies (Table 5) . One patient with T1D had all seven autoantibodies whereas one had NPY-LA only. Most of the T2D patients (18/26, 69%) were negative for all autoantibodies.
NPY and islet autoantibodies during follow-up of long-term T1D patients
The subgroup of 32 patients with long-term T1D was analyzed after duration of 21-50 years and 5-8 years after baseline (Table 2 ). In general, 27/32 (84%) initially autoantibody positive T1D
patients, 17/32 (53%) remained autoantibody positive (p=0.002) during follow-up. The NPY-LA frequency decreased from 9/32 (28%) to 0/32 (0%) and for NPY-PA from 5/32 (16%) to 0/32 (0%) ( Table 6 ). The median levels of NPY-LA declined from 34 U/mL to 21 U/mL (p<0.001) NPY-LA and NPY-PA levels correlated (R 2 =0.446; p=0.011) at baseline, however this correlation was essentially lost (R 2 =0.348; p=0.051) at follow-up.
In the same group of 32 patients, the frequency of ZnT8A decreased from 14/32 (44%) to 4/32 (13%). Also, the median levels of the ZnT8A variants were lower at the time of follow-up (ZnT8RA, p<0.001; ZnT8WA, p<0.001; ZnT8QA, p<0.001) compared to baseline ( Figure 5 , panels A-C).
The frequency of GADA (p=0.687) and IA-2A (p=1.0) did not change between baseline and follow-up (Table 6 ). The levels of GADA (p=0.005) and IA-2A (p<0.001) declined during follow-up ( Figure 5 , panels D-E).
It was also tested if NPY-LA and NPY-PA correlated to any of the islet autoantibodies in the 32 T1D patients. 
NPYA and neuropathy in re-examined T1D patients
Peripheral neuropathy was related to cardiac autonomic neuropathy (R 2 =0.328; p<0.001) in the long-term follow-up patients with T1D ( Figure 6 ). It was observed that males (12/14; 86%), more often had an abnormal cardiac autonomic neuropathy (cut-off at -1.64) compared to females (2/14; 14%) (p=0.007). Taking these gender differences into account, we also addressed the question whether peripheral, autonomic, or both, neuropathies in the 32 T1D patients reexamined after 5-8 years were associated to any of the autoantibodies. Neither peripheral nor cardiac autonomic neuropathy was related to the presence or levels of the NPYA nor was there a correlation with ZnT8A, GADA or IA-2A.
Discussion
In this study, we established an autoantibody radiobinding assay to assess the levels and frequency of two NPY autoantibody variants (NPY-LA and NPY-PA) in patients with T1D and T2D compared to controls. The major findings were as follows. First, newly diagnosed T1D patients had 29% NPY-LA alone, 29% NPY-PA alone but 20% being double positive. Second, long duration T1D patients had 23% and 19% compared to 12% and 23%, respectively, in the patients with T2D using the control 97.5 th percentile as cut-off. Previously, NPY-LA was reported in 9% of T1D patients newly diagnosed below the age of 19 years [6] . It was therefore of interest that the present group of patients not only were diagnosed as adults but also had disease duration of median 26 years at the time when the first samples were obtained (referred to as baseline). More remarkably, at follow-up the levels had decreased significantly. These findings were comparable to GADA, IA-2A and the ZnT8A, which showed decreased levels during follow-up despite the lack of correlation between the levels of any of the two NPYA with GADA and IA-2A. The loss of autoantibodies over time in the follow-up samples may be due to both storage and an unknown number of freezing and thawing cycles.
Other studies of newly diagnosed patients with T1D in active follow-up [27] will be needed to determine if NPYA will decrease rapidly after diagnosis such as IA-2A and ZnT8A or slowly similar to GADA [28] . It should also be noted that the present group of long-term T1D patients had frequencies of GADA, IA-2A and ZnT8A at baseline ranging between 31-52%.
Another major finding was the comparable frequencies of NPYA among the patients with T2D.
These patients were also long-term and their duration amounted to an average of 23 years. The NPYA in this group of patients may be easily explained by the possibility that at least some of these patients might have had autoimmune diabetes (LADA) as opposed to T2D. In the event that LADA would be the classification, none of the patients would qualify as neither GADA nor IA-2A were found among the T2D patients. If the ZnT8A would allow these patients to be classified as LADA, 23% of our T2D patients would be classified with LADA. The appearances of islet antibodies GADA, IA-2A and ZnT8A predict beta-cell failure in T1D, while in T2D, where they are less common, have a higher preserved beta-cell function [41] . Yet, the possible relevance of autoantibodies in neuropathy is less known. It has been reported that increased GADA levels at onset were associated with retinopathy in patients with T1D [42]. In addition, higher GADA levels were found in T1D patients with retinopathy and nephropathy compared to T1D patients without complications, which may suggest GADA as a complication predictor [43] . Also, T1D patients with higher GADA levels was reported to have a slower motor nerve conduction velocity compared to T1D patients with lower GADA levels [19] . The ability to predict peripheral and autonomic neuropathy by studying the correlation with the islet autoantibody levels and frequency in patients with T1D was also investigated in the present study. Neither of the peripheral nor the autonomic neuropathy correlated to the presence of the autoantibodies in the patients. There was a clear difference of the abnormal autonomic neuropathy between genders, but this difference was not related to any of the islet autoantibodies, including NPY-LA or NPY-PA. This lack of association may be due to the small number of T1D patients (n=32). Thus, we cannot conclude that the presently used autoantibodies can predict presence of peripheral or autonomic neuropathy in T1D. We noted that 6/26 T2D patients (5/6 were overweight or obese, data not shown) had at least one of the NPYA variants.
Similarly, ZnT8A were also positive in 5/6 overweight or obese T2D. Although there was no relation between NPYA (or ZnT8A) and neuropathy in the T1D patients, it cannot be excluded that there may be such a relation in T2D. Unfortunately, we did not have any neuropathy data of the T2D patients. Further studies are warranted to investigate this possibility.
It is known that the ZnT8 transporter is targeted by three ZnT8A variants dependent on the T2D indicated that the structure of the mature NPY protein is dependent on the amino acid residue at SNP rs16139 [12] resulting in an altered packaging and secretion of NPY [13] . The genetic polymorphisms of the patients in this study were not known. It would be of interest to determine if autoantibodies against NPY are related to the L7P genetic polymorphism. Our kappa analysis suggests that there was substantial agreement between the two NPYA variants, which suggest that NPY L7P polymorphisms may not be as strong as the ZnT8 R325W polymorphism [24] to determine a crucial epitope. In order to detect specific serum autoreactivity against either NPY-P or NPY-L protein, displacement assays with a cold inhibitor was used. However, specific sera were rare and further analysis of large number of sera will be needed to search for possible isoform-specific sera. It cannot be excluded that individuals may have such autoantibodies.
Conclusions
Autoantibodies against both NPY-L and NPY-P were present in long-term T1D and T2D
patients, and the NPYA levels declined during follow-up. Neither the frequency nor the titers of the NPYA variants were related to peripheral or cardiac autonomic neuropathy in the T1D patients. We conclude that NPY fulfills the criteria for a minor autoantigen in T1D. It cannot be excluded that NPY autoimmunity may contribute to the pathogenesis in long-term T1D, perhaps also in T2D. Table 2 . Demographic data of patients with long-term Type 1 (n=48) diabetes (T1D) and Type 2 (n=26) diabetes (T2D) at baseline compared to healthy controls (n=398), and long-term T1D patients (n=32) at follow-up.
The Z-score reflects the peripheral nerve function in the leg (peroneal and sural nerves) and expressed in agecorrected values. The E/I Z-score reflects the parasympathetic vagal nerve function and expressed in age-corrected
values. E/I Z-score values less than −1.64 SD (95% confidence interval, one-sided test) below the age-related reference values were considered abnormal.
Abbreviations: T1D, Type 1 diabetes; T2D, Type 2 diabetes; N.A. is not applicable. Number of patients is indicated as followed; a=25; b=27; c=31.
BASELINE T1D T2D Controls
P-values are shown as *T1D patients compared to controls and **T2D patients compared to controls. Differences of autoantibody frequency between patients and controls were considered significant when p-value of <0.05 was Table 4 . Agreement of NPY-L (Leucine) and NPY-P (Proline) autoantibodies with ZnT8, GAD65 and IA-2 islet autoantibodies to mark autoimmunity in long-term T1D and T2D patients at base-line.
A P-value < 0.05 was considered significant, a= ranked by agreement to mark autoimmunity (kappa). 
